Диссертация (1139687), страница 35
Текст из файла (страница 35)
Miyazawa, M. Shindo, T. Shimada // Drug Metab Dispos.– 2001. – Vol. 29. – N 2. – P. 200–205.244. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but notgamma-tocotrienol in mice / D. Kluth [et al.] // Free Radic Biol Med. – 2005. – Vol. 38– P. 507–514.245. Molecularly Imprinted Polymers (MIP) in Electroanalysis of Proteins. /V. V.
Shumyantseva [et al.] // Biochemistry (Moscow) Supplement Series B:Biomedical Chemistry – 2016. – Vol. 10. – N 2. – P. 145–151.246. Molecular lego: Design of molecular assemblies of p450 enzymes fornanobiotechnology / G. Gilardi [et al.] // Biosens. Bioelectron. – 2002.
– Vol. 17 –P. 133–145.247. Nebert, D. W. Clinical importance of the cytochromes P450 /D. W. Nebert, D. W. Russell // Lancet. – 2002. – Vol. 360 – P. 1155–1162.248. Optimization in Drug Discovery: In Vitro Methods (Methods inPharmacology and Toxicology) / ed. Z. Yan, G. Caldwell. – 2nd edition. – Totowa:Humana Press Inc. – 2014. – 597 p.249. Oral treatment with alpha-lipoic acid improves symptomatic diabeticpolyneuropathy: the SYDNEY 2 trial / D. Ziegler [et al.] // Diabetes Care. – 2006. –Vol. 29. – N 11. – P.
2365–2370.250. P450 superfamily: update on new sequences, gene mapping, accessionnumbers and nomenclature / D. R. Nelson [et al.] // Pharmacogenetics. – 1996. – Vol. 6.– N 1. – P. 1–42.251. Packer, L. Alpha-lipoic acid: a metabolic antioxidant which regulates NFkappa B signal transduction and protects against oxidative injury / L.
Packer // DrugMetab Rev. – 1998. – Vol. 30. – N 2. – P. 245–275.252. Parker, R. S. Cytochrome P4503A-dependent metabolism of tocopherolsand inhibition by sesamin / R. S. Parker, T. J. Sontag, J. E. Swanson // BiochemBiophys Res Commun. – 2000. – Vol. 277 – P. 531–534.219253. Perret, A. Electron shuttle between membrane-bound cytochrome P4503A4 and b5 rules uncoupling mechanisms / A. Perret, D. Pompon // Biochemistry. –1998. – Vol.
37. – N 33. – P. 11412–11424.254. Pharmacogenomics knowledge for personalized medicine / M. WhirlCarrillo [et al.] // Clin. Pharmacol. Ther. – 2012. – Vol. 92 – P. 414–417.255. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel,controlled-release formulation of alpha-lipoic acid / J. L. Evans [et al.] // Endocr Pract.– 2002. – Vol. 8. – N 1. – P.
29–35.256. Plasma coenzyme Q (ubiquinone) concentrations in patients treated withsimvastatin / G. Watts [et al.] // J Clin Pathol. – 1993. – Vol. 46. – N 11 – P. 1055–1057.257. Pochapsky,T. C.Conformationalplasticityandstructure/functionrelationships in cytochromes P450 / T. C. Pochapsky, S. Kazanis, M. Dang // Antioxid.Redox Signal.
– 2010. – Vol. 13. – N 8. – P. 1273–1296.258. Porter, T. D. Jud Coon: 35 years of P450 research, a synopsis of P450history / T. D. Porter // Drug Metab. Dispos. – 2004. – Vol. 32. – N 1 – P. 1–6.259. Protein and electrode engineering for the covalent immobilization of p450bmp on gold / V. E. V. Ferrero [et al.] // Anal. Chem.
– 2008. – Vol. 80 – P. 8438–8446.260. Protein Electrochemistry: Application in Medicine. A Review /E. V. Suprun [et al.] // Electrochimica Acta. – 2014. – Vol. 140. – P. 72–82.261. Putzbach, W. Immobilization techniques in the fabrication of nanomaterialbased electrochemical biosensors: A review / W. Putzbach, N. Ronkainen // Sensors.
–2013. – Vol. 13. – N 4. – P. 4811–4840.262. Qualitative analysis of the role of metabolites in inhibitory drug-druginteractions: literature evaluation based on the metabolism and transport druginteraction database / Isoherranen, N. [et al.] // Chem Res Toxicol. – 2009. – Vol. 22. –N 2. – P. 294–298.263. (R)-alpha-lipoic acid reverses the age-associated increase in susceptibilityof hepatocytes to tert-butylhydroperoxide both in vitro and in vivo / T.
M. Hagen [et al.]// Antioxid Redox Signal. – 2000. – Vol. 2. – N 3. – P. 473–483.220264. (R)-alpha-lipoic acid treatment restores ceramide balance in aging ratcardiac mitochondria / J. S. Monette [et al.] // Pharmacol Res. – 2011. – Vol. 63. – N 1.– P. 23–29.265. Reconstituted liver microsomal enzyme system that hydroxylates drugs,other foreign compounds, and endogenous substrates.
I. Determination of substratespecificity by the cytochrome P-450 and P-448 fractions / A. Y. H. Lu [et al.] //Biochem Biophys Res Commun. – 1971. – Vol. 42. – N 6. – P. 1200–1206.266. Reed, L. J. A trail of research from lipoic acid to alpha-keto aciddehydrogenase complexes / L. J. Reed // J Biol Chem.
– 2001. – Vol. 276. – N 42. –P. 38329–38336.267. Regioselective hydroxylation of omeprazole enantiomers by bacterialCYP102A1 mutants / S. H. Ryu [et al.] // Drug Metab Dispos. –2014. – Vol. 42. – N 9/– P. 1493–1497.268. Relling,M. V.CPIC:ClinicalPharmacogeneticsImplementationConsortium of the Pharmacogenomics Research Network / M. V. Relling, T. E.
Klein //Clin Pharmacol Ther. – 2011. – Vol. 89. – N 3. – P. 464–467.269. Rendic, S. Human cytochrome p450 enzymes: A status report summarizingtheir reactions, substrates, inducers, and inhibitors / S. Rendic, F. J. D. Carlo // DrugMetab. Rev. – 1997. – Vol. 29. – P. 413–580.270. Rendic, S. Contributions of human enzymes in carcinogen metabolism /S. Rendic, F.
P. Guengerich // Chem Res Toxicol. – 2012. – Vol. 25 – P. 1316–1383.271. Ripps, H. Review: Taurine: A “very essential” amino acid / H. Ripps,W. Shen // Mol Vis. – 2012. – Vol. 18 – P. 2673–2686.272. Ronkainen,N. J.Electrochemicalbiosensors/N. J. Ronkainen,H. B. Halsall, W. R. Heineman // Chem Soc Rev.
– 2010. – Vol. 39. – N 5. – P. 1747–1763.273. Sadeghi, S. J. Breakthrough in P450 bioelectrochemistry and futureperspectives / S. J. Sadeghi, A. Fantuzzi, G. Gilardi // Biochim Biophys Acta. – 2011. –Vol. 1814. – N 1. – P. 237–248.221274. Sadeghi, S. J. Chimeric P450 enzymes: activity of artificial redox fusionsdriven by different reductases for biotechnological applications / S. J.
Sadeghi,G. Gilardi // Biotechnol Appl Biochem. – 2013. – Vol. 60. – N 1. – P. 102–110.275. Schneider, E. Cytochrome P450 (CYP) enzymes and the development ofCYP biosensors / E. Schneider, D. S. Clark // Biosensors and Bioelectronics. – 2013. –Vol. 39. – N 1. – P. 1– 3.276. Screening of Potential Substrates or Inhibitors of Cytochrome P450 17A1(CYP17A1) by Electrochemical Methods / V. V.
Shumyantseva [et al.] // Biochemistry(Moscow) Supplement Series B: Biomedical Chemistry. – 2011. – Vol. 5. – N 1. –P. 55–59.277. Sedimentation and other properties of the reconstituted liver microsomalmixed-functionoxidasesystemcontainingcytochromeP450,reducedtriphosphopyridine nucleotide-cytochrome P450 reductase, and phosphatidylcholine /A. P. Autor // Mol. Pharmacol. – 1973. – Vol.
9. – P. 93–104.278. Semiphysiologically based pharmacokinetic models for the inhibition ofmidazolam clearance by diltiazem and its major metabolite / X. Zhang [et al.] // DrugMetab Dispos. – 2009. – Vol. 37. – N 8. – P. 1587–1597.279. Sensor systems for medical application based on hemoproteins andnanocomposite materials / V. V. Shumyantseva [et al.] // Biochemistry (Moscow)Supplement Series B: Biomedical Chemistry.
– 2010. – Vol. 4. – N 1 – P. 25–36.280. Shafiee, A. Purification and reconstitution of the electron transportcomponents for 6-deoxyerythronolide B hydroxylase, a cytochrome P-450 enzyme ofmacrolide antibiotic (erythromycin) biosynthesis /A. Shafiee, C. R. Hutchinson //J. Bacteriol. – 1988. – Vol. 170. – N 4. – P. 1548–1553.281. Shapiro, L. E. Drug interactions: proteins, pumps, and P-50s /L. E. Shapiro, N. H.
Shear // J Am Acad Dermatol. – 2002. – Vol. 47 – P. 467–484.282. Shay, K.P. Age-associated impairment of Akt phosphorylation in primaryrat hepatocytes is remediated by alpha-lipoic acid through PI3 kinase, PTEN, and PP2A/ K. P. Shay, T. M. Hagen // Biogerontology. – 2009. – Vol. 10. – N 4. – P. 443–456.222283. Shen, D. D. Enzyme-catalyzed processes of first-pass hepatic and intestinaldrug extraction / D. D. Shen, K.
L. Kunze, K. E. Thummel // Adv Drug Deliv Rev. –1997. – Vol. 7 – P. 99–127.284. Simvastatin and niacin, antioxidant vitamins, or the combination for theprevention of coronary disease / B. G. Brown [et al.] // N Engl J Med. – 2001. –Vol. 345. – N 22. – P. 1583–1592.285. Smith D. A. Metabolites in safety testing (MIST): considerations ofmechanisms of toxicity with dose, abundance, and duration of treatment / D. A. Smith,R.
S. Obach // Chemical Research in Toxicology. – 2009. – Vol. 22. – N 2. – P. 267–279.286. Shumyantseva, V. V. Electrochemical reduction of cytochrome p450 as anapproach to the construction of biosensors and bioreactors / V. V. Shumyantseva,T. V. Bulko, A. I. Archakov // J. Inorg.
Biochem. – 2005. – Vol. 99. – N 5. – P. 1051–1063.287. Stereochemical aspects of itraconazole metabolism in vitro and in vivo /K. L. Kunze [et al.] // Drug Metab. Dispos. – 2006. – Vol. 34. – P. 583–590.288. Stimulation of glucose uptake by the natural coenzyme alpha-lipoicacid/thioctic acid: participation of elements of the insulin signaling pathway /D. E. Estrada [et al.] // Diabetes. – 1996.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
